Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from SKAN Group AG ( (CH:SKAN) ).
SKAN Group AG, a leading supplier of aseptic isolator systems and process solutions for pharma and biotech, continued to benefit from robust demand for high-end filling lines, particularly for oncology and biologics, in 2025. The company strengthened its high-end market position with a roughly 50% offer success rate and expanded its digital and consumables capabilities through the acquisitions of software specialist Metronik and transfer-systems provider ABC Transfer.
Order intake rose 3.1% to CHF 370.6 million, lifting the backlog to CHF 346.1 million and giving good revenue visibility, though a portion faces potential cancellation risk. Net sales fell 7.7% to CHF 333.3 million and EBITDA dropped to CHF 38.6 million with an 11.6% margin as large vaccine projects were postponed, shifting revenues into the current year and weighing on profitability.
The Equipment & Solutions segment saw sharply lower sales and margins due to these project delays, partly offset by pre-production of standard isolators and continued investment in integrated process solutions and robotics-based systems. By contrast, Services & Consumables grew strongly, with sales up 28.9% and contributing 35% of group revenue, a strategic mix shift aimed at improving margins over the medium term.
Operating cash flow increased 37.3% to CHF 64.1 million on better working capital despite higher investment in Pre-Approved Services, while the equity ratio fell to 26.5% after goodwill accounting for the two acquisitions. The board will propose a CHF 0.22 per-share dividend and is seeking to add digital and AI expert Christian Schlögel to the board as SKAN accelerates its software and digital integration offering, while long-serving director Patrick Schär steps down.
The most recent analyst rating on (CH:SKAN) stock is a Sell with a CHF54.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.
More about SKAN Group AG
SKAN Group AG is a world market leader in high-quality isolator systems for aseptic production processes in the pharmaceutical and biotech industry. The Swiss group focuses on process solutions for aseptic filling of biopharmaceutical active ingredients, especially oncology applications, large-molecule injectables and complex ADC production lines, positioning itself in the high-end segment of the global isolator market.
Average Trading Volume: 32,758
Technical Sentiment Signal: Sell
Current Market Cap: CHF985.9M
Find detailed analytics on SKAN stock on TipRanks’ Stock Analysis page.